title: Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
abstract: Over the past two decades, several studies have suggested that regimens that contain anthracyclines are more effective than those that do not. A meta-analysis by the 2005 Early Breast Cancer Trialists' Collaborative Group confirmed that about 6 months of anthracycline-based polychemotherapy in the adjuvant setting reduced the yearly death rate from breast cancer by about 38% for women younger than 50 years and by 20% for women aged 50-69 years. Although this meta-analysis found that survival was better with regimens that contain anthracycline than with regimens based on cyclophosphamide, methotrexate, and fluorouracil, the best use of anthracycline-based regimens remains unclear. Adjuvant regimens in use can be categorised into three groups: standard-dose anthracycline; escalated-dose epirubicin; and anthracyclines and taxanes. The duration of treatment and combination of dose and drugs varies between these three categories. We reviewed the three types of regimen to establish which provide a better outcome in terms of safety, efficacy, cost, and convenience to patients. We found that both escalated-dose epirubicin and anthracycline-taxane regimens were most effective in terms of disease-free survival and overall survival. Of the specific anthracycline-based regimens, the docetaxel, doxorubicin, and cyclophosphamide regimen (TAC); the fluorouracil, 100 mg epirubicin, and cyclophosphamide regimen (FEC100); and the cyclophosphamide, epirubicin, and fluorouracil regimen (CEF) produced the greatest proportional decreases in 5-year death rate.
authors.affiliation: Division of Medical Oncology and Haematology, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, Canada. Maureen.Trudeau@sw.ca
authors.forename: Maureen
authors.initials: M
authors.lastname: Trudeau
authors.forename: Flay
authors.initials: F
authors.lastname: Charbonneau
authors.forename: Karen
authors.initials: K
authors.lastname: Gelmon
authors.forename: Kara
authors.initials: K
authors.lastname: Laing
authors.forename: Jean
authors.initials: J
authors.lastname: Latreille
authors.forename: John
authors.initials: J
authors.lastname: Mackey
authors.forename: Deanna
authors.initials: D
authors.lastname: McLeod
authors.forename: Kathy
authors.initials: K
authors.lastname: Pritchard
authors.forename: Louise
authors.initials: L
authors.lastname: Provencher
authors.forename: Shailendra
authors.initials: S
authors.lastname: Verma
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D043823:Taxoids; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate